Research programme: autoimmune/inflammatory disorders - ViRexx
Alternative Names: Autoimmune/inflammatory disorders research programme: ViRexxLatest Information Update: 07 Feb 2005
Price :
$50 *
At a glance
- Originator ViRexx Medical Corp
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 13 Dec 2004 AltaRex has been acquired and merged into ViRexx Medical Corp
- 25 Feb 2003 Discontinued - Preclinical for Autoimmune disorders in Canada (unspecified route)
- 07 Jun 2001 Preclinical development for Autoimmune disorders in Canada (Unknown route)